Asset profile
veligrotug · Viridian Therapeutics (VRDN)
- Indication
- thyroid eye disease
- Also known as
- VRDN-001, Lumvoa, veligrotug-vvze, VRDN-003
Company
VRDNViridian Therapeutics
VRDNViridian TherapeuticsViridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for i…
On the calendar
30
Jun 2026
Jun 30, 2026
123 days ago
VRDNViridian TherapeuticsTimeline
Newest first.
Aug 6, 2026
11:05 AM
VRDNViridian TherapeuticsJun 26, 2026
12:00 AM
VRDNViridian TherapeuticsFeb 26, 2026
12:13 PM
VRDNViridian TherapeuticsRegistered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT06179875 | Phase 3 | Completed | Apr 25, 2025 | 139 | 18 of 45 sites in the United States |
| NCT06384547 | Phase 3 | Completed | May 1, 2025 | 231 | 26 of 50 sites in the United States |
| NCT05176639 | Phase 3 | Completed | Jul 15, 2024 | 113 | 29 of 53 sites in the United States |
| NCT06021054 | Phase 3 | Completed | Nov 4, 2024 | 188 | 23 of 57 sites in the United States |
More from Viridian Therapeutics
Other drugs and candidates from the same company tracked in this sector.